Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

por Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, A M, Ledermann, J A
Publicado 2011

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells

por Sudhagar, S, Sathya, S, Lakshmi, B S
Publicado 2011

GSTPi-positive tumour microenvironment-associated fibroblasts are significantly associated with GSTPi-negative cancer cells in paired cases of primary invasive breast cancer and ax...

por Chaiwun, B, Sukhamwang, N, Trakultivakorn, H, Saha, B, Young, L, Tsao-Wei, D, Naritoku, W Y, Groshen, S, Taylor, C R, Imam, S A
Publicado 2011

Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus

por Dunn, J M, Hveem, T, Pretorius, M, Oukrif, D, Nielsen, B, Albregtsen, F, Lovat, L B, Novelli, M R, Danielsen, H E
Publicado 2011

A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma

por Burton, C, Linch, D, Hoskin, P, Milligan, D, Dyer, M J S, Hancock, B, Mouncey, P, Smith, P, Qian, W, MacLennan, K, Jack, A, Webb, A, Cunningham, D
Publicado 2006

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

por Sugio, K, Uramoto, H, Ono, K, Oyama, T, Hanagiri, T, Sugaya, M, Ichiki, Y, So, T, Nakata, S, Morita, M, Yasumoto, K
Publicado 2006

Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia

por Sanders, P M, Russell, S T, Tisdale, M J
Publicado 2005

A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures

por Sandanayake, N S, Sinclair, J, Andreola, F, Chapman, M H, Xue, A, Webster, G J, Clarkson, A, Gill, A, Norton, I D, Smith, R C, Timms, J F, Pereira, S P
Publicado 2011

Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer

por Zeleniuch-Jacquotte, A, Shore, R E, Afanasyeva, Y, Lukanova, A, Sieri, S, Koenig, K L, Idahl, A, Krogh, V, Liu, M, Ohlson, N, Muti, P, Arslan, A A, Lenner, P, Berrino, F, Hallmans, G, Toniolo, P, Lundin, E
Publicado 2011

Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma

por Gattolliat, C-H, Thomas, L, Ciafrè, S A, Meurice, G, Le Teuff, G, Job, B, Richon, C, Combaret, V, Dessen, P, Valteau-Couanet, D, May, E, Busson, P, Douc-Rasy, S, Bénard, J
Publicado 2011

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation

por Fujisaka, Y, Sugiyama, T, Saito, H, Nagase, S, Kudoh, S, Endo, M, Sakai, H, Ohashi, Y, Saijo, N
Publicado 2011

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells

por Yashiro, M, Qiu, H, Hasegawa, T, Zhang, X, Matsuzaki, T, Hirakawa, K
Publicado 2011

The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study

por Gormley, J A, Hegarty, S M, O'Grady, A, Stevenson, M R, Burden, R E, Barrett, H L, Scott, C J, Johnston, J A, Wilson, R H, Kay, E W, Johnston, P G, Olwill, S A
Publicado 2011

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

por Hofstetter, G, Berger, A, Schuster, E, Wolf, A, Hager, G, Vergote, I, Cadron, I, Sehouli, J, Braicu, E I, Mahner, S, Speiser, P, Marth, C, Zeimet, A G, Ulmer, H, Zeillinger, R, Concin, N
Publicado 2011

Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients

por Lundin, K B, Henningson, M, Hietala, M, Ingvar, C, Rose, C, Jernström, H
Publicado 2011

Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial

por Castañon, A, Tristram, A, Mesher, D, Powell, N, Beer, H, Ashman, S, Rieck, G, Fielder, H, Fiander, A, Sasieni, P
Publicado 2012

Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression

por Scaggiante, B, Dapas, B, Bonin, S, Grassi, M, Zennaro, C, Farra, R, Cristiano, L, Siracusano, S, Zanconati, F, Giansante, C, Grassi, G
Publicado 2012

Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer

por Zeestraten, E C M, Maak, M, Shibayama, M, Schuster, T, Nitsche, U, Matsushima, T, Nakayama, S, Gohda, K, Friess, H, van de Velde, C J H, Ishihara, H, Rosenberg, R, Kuppen, P J K, Janssen, K-P
Publicado 2012

Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game

por Basanta, D, Scott, J G, Fishman, M N, Ayala, G, Hayward, S W, Anderson, A R A
Publicado 2012

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pa...

por Goldstein, D, Spry, N, Cummins, M M, Brown, C, van Hazel, G A, Carroll, S, Selva-Nayagam, S, Borg, M, Ackland, S P, Wratten, C, Shapiro, J, Porter, I W T, Hruby, G, Horvath, L, Bydder, S, Underhill, C, Harvey, J, Gebski, V J
Publicado 2012